Acrivastine in allergic rhinitis: a review of clinical experience.
Acrivastine is an antihistamine with reduced sedating potential. This comprehensive review of clinical experience with acrivastine in allergic rhinitis considers all currently available data both published and, as yet, unpublished. Unequivocal evidence of the efficacy of 8 mg acrivastine three times daily for the control of symptoms of seasonal allergic rhinitis has been provided by 11 placebo-controlled studies involving almost 1000 patients. Additional trials have generated further supportive data as well as evidence for the use of acrivastine in the treatment of perennial allergic rhinitis. In common with most antihistamines, acrivastine alone has limited effect on the symptom of blocked nose. In a further series of 11 studies, mainly conducted in the USA, the combination of 8 mg acrivastine plus 60 mg pseudoephedrine was found to control not only the histamine-mediated symptoms of allergic rhinitis but also blocked nose. There were few adverse events associated with the use of acrivastine and the small increase in incidence of drowsiness over that found with placebo was similar to that observed for terfenadine. The marked absence of other signs of significant depression of the central nervous system (or anticholinergic activity) suggests that acrivastine will be an important addition for the antihistaminic control of symptoms of allergic rhinitis.
Bojkowski
C J
CJ
Wellcome Research Laboratories, Beckenham, UK.
Gibbs
T G
TG
Hellstern
K H
KH
Major
E W
EW
Mullinger
B
B
D002986:Clinical Trials as Topic; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D011725:Pyridines / Q000627:therapeutic use*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D014311:Triprolidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*
D006634:Histamine H1 Antagonists; D011725:Pyridines; D014311:Triprolidine; C043648:acrivastine